The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules

J. Kaiser, C. A. Bickel, B. S. Bochner, R. P. Schleimer

Research output: Contribution to journalArticle

Abstract

An important early event in the formation of the allergic late phase cellular infiltrate is the adhesion of eosinophils to vascular endothelium. Because glucocorticoids are potent inhibitors of this late-phase inflammatory reaction, we examined the effect of the glucocorticoid budesonide on in vitro adhesion of human eosinophils to cultured human umbilical vein endothelial cells (HUVEC). Pretreatment of eosinophils, HUVEC or both with budesonide (10-7 M) did not inhibit either baseline adhesion or that stimulated by interleukin-1β (50 U/ml, 4 hr) or interleukin-4 (100 U/ml, 21-23 hr) or the leukocyte activators N-formyl-methionyl-leucyl-phenylalanine (10-6 M, 10 min) or platelet-activating factor (10-6 M, 10 min). Pretreatment of HUVEC with budesonide also failed to affect expression of the adhesion molecules E- selectin, intercellular adhesion molecule-1, or vascular cell adhesion molecule-1 on resting HUVEC or after stimulation with interleukin-1β (10 U/ml, 4 hr), tumor necrosis factor (6 U/ml, 4 hr) or interleukin-4 (50 U/ml, 24 hr). Because budesonide failed to inhibit stimulus-induced eosinophil adhesion responses or endothelial adhesion molecule expression, we speculate that glucocorticoids inhibit the formation of eosinophil-enriched tissue infiltrates by inhibiting the production rather than the activity of eosinophil- or endothelial-activating factors or by altering the survival of eosinophils in tissues.

Original languageEnglish (US)
Pages (from-to)245-249
Number of pages5
JournalJournal of Pharmacology and Experimental Therapeutics
Volume267
Issue number1
StatePublished - 1993

Fingerprint

Budesonide
Eosinophils
Glucocorticoids
Endothelial Cells
Human Umbilical Vein Endothelial Cells
Interleukin-1
Interleukin-4
N-Formylmethionine Leucyl-Phenylalanine
E-Selectin
Vascular Cell Adhesion Molecule-1
Platelet Activating Factor
Vascular Endothelium
Intercellular Adhesion Molecule-1
Interleukin-10
Leukocytes
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Pharmacology

Cite this

The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules. / Kaiser, J.; Bickel, C. A.; Bochner, B. S.; Schleimer, R. P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 267, No. 1, 1993, p. 245-249.

Research output: Contribution to journalArticle

@article{d49fd94d3bfe4e48a35419b0926f8b22,
title = "The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules",
abstract = "An important early event in the formation of the allergic late phase cellular infiltrate is the adhesion of eosinophils to vascular endothelium. Because glucocorticoids are potent inhibitors of this late-phase inflammatory reaction, we examined the effect of the glucocorticoid budesonide on in vitro adhesion of human eosinophils to cultured human umbilical vein endothelial cells (HUVEC). Pretreatment of eosinophils, HUVEC or both with budesonide (10-7 M) did not inhibit either baseline adhesion or that stimulated by interleukin-1β (50 U/ml, 4 hr) or interleukin-4 (100 U/ml, 21-23 hr) or the leukocyte activators N-formyl-methionyl-leucyl-phenylalanine (10-6 M, 10 min) or platelet-activating factor (10-6 M, 10 min). Pretreatment of HUVEC with budesonide also failed to affect expression of the adhesion molecules E- selectin, intercellular adhesion molecule-1, or vascular cell adhesion molecule-1 on resting HUVEC or after stimulation with interleukin-1β (10 U/ml, 4 hr), tumor necrosis factor (6 U/ml, 4 hr) or interleukin-4 (50 U/ml, 24 hr). Because budesonide failed to inhibit stimulus-induced eosinophil adhesion responses or endothelial adhesion molecule expression, we speculate that glucocorticoids inhibit the formation of eosinophil-enriched tissue infiltrates by inhibiting the production rather than the activity of eosinophil- or endothelial-activating factors or by altering the survival of eosinophils in tissues.",
author = "J. Kaiser and Bickel, {C. A.} and Bochner, {B. S.} and Schleimer, {R. P.}",
year = "1993",
language = "English (US)",
volume = "267",
pages = "245--249",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - The effects of the potent glucocorticoid budesonide on adhesion of eosinophils to human vascular endothelial cells and on endothelial expression of adhesion molecules

AU - Kaiser, J.

AU - Bickel, C. A.

AU - Bochner, B. S.

AU - Schleimer, R. P.

PY - 1993

Y1 - 1993

N2 - An important early event in the formation of the allergic late phase cellular infiltrate is the adhesion of eosinophils to vascular endothelium. Because glucocorticoids are potent inhibitors of this late-phase inflammatory reaction, we examined the effect of the glucocorticoid budesonide on in vitro adhesion of human eosinophils to cultured human umbilical vein endothelial cells (HUVEC). Pretreatment of eosinophils, HUVEC or both with budesonide (10-7 M) did not inhibit either baseline adhesion or that stimulated by interleukin-1β (50 U/ml, 4 hr) or interleukin-4 (100 U/ml, 21-23 hr) or the leukocyte activators N-formyl-methionyl-leucyl-phenylalanine (10-6 M, 10 min) or platelet-activating factor (10-6 M, 10 min). Pretreatment of HUVEC with budesonide also failed to affect expression of the adhesion molecules E- selectin, intercellular adhesion molecule-1, or vascular cell adhesion molecule-1 on resting HUVEC or after stimulation with interleukin-1β (10 U/ml, 4 hr), tumor necrosis factor (6 U/ml, 4 hr) or interleukin-4 (50 U/ml, 24 hr). Because budesonide failed to inhibit stimulus-induced eosinophil adhesion responses or endothelial adhesion molecule expression, we speculate that glucocorticoids inhibit the formation of eosinophil-enriched tissue infiltrates by inhibiting the production rather than the activity of eosinophil- or endothelial-activating factors or by altering the survival of eosinophils in tissues.

AB - An important early event in the formation of the allergic late phase cellular infiltrate is the adhesion of eosinophils to vascular endothelium. Because glucocorticoids are potent inhibitors of this late-phase inflammatory reaction, we examined the effect of the glucocorticoid budesonide on in vitro adhesion of human eosinophils to cultured human umbilical vein endothelial cells (HUVEC). Pretreatment of eosinophils, HUVEC or both with budesonide (10-7 M) did not inhibit either baseline adhesion or that stimulated by interleukin-1β (50 U/ml, 4 hr) or interleukin-4 (100 U/ml, 21-23 hr) or the leukocyte activators N-formyl-methionyl-leucyl-phenylalanine (10-6 M, 10 min) or platelet-activating factor (10-6 M, 10 min). Pretreatment of HUVEC with budesonide also failed to affect expression of the adhesion molecules E- selectin, intercellular adhesion molecule-1, or vascular cell adhesion molecule-1 on resting HUVEC or after stimulation with interleukin-1β (10 U/ml, 4 hr), tumor necrosis factor (6 U/ml, 4 hr) or interleukin-4 (50 U/ml, 24 hr). Because budesonide failed to inhibit stimulus-induced eosinophil adhesion responses or endothelial adhesion molecule expression, we speculate that glucocorticoids inhibit the formation of eosinophil-enriched tissue infiltrates by inhibiting the production rather than the activity of eosinophil- or endothelial-activating factors or by altering the survival of eosinophils in tissues.

UR - http://www.scopus.com/inward/record.url?scp=0027358752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027358752&partnerID=8YFLogxK

M3 - Article

C2 - 7693913

AN - SCOPUS:0027358752

VL - 267

SP - 245

EP - 249

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -